
Human & Mouse CD3/CD28 ActiveBeads™





Signal 1 involves TCR binding to MHC presented antigen, followed by Signal 2 mediated by CD28 on T cell and CD80/CD86 co-stimulatory molecule on APC. Abnova provides CD3/CD28 ActiveBeads™ which replicate T cell activation process without APC involvement. These 4.5 µm ActiveBeads™ are valuable tools in both human and mouse T cell research, enabling immunologic and adoptive T cell studies in tumors, autoimmune diseases, and regulatory dysfunctions. Adoptive T cell immunotherapy has diverse applications in targeted therapies including Donor Lymphocyte Infusions (DLIs), Chimeric Antigen Receptor (CAR) T Cell Therapy, Tumor-Infiltrating Lymphocytes (TILs), and T-Cell Receptor (TCR)-Engineered T Cells. Abnova's Human CD3/CD28 ActiveBeads™ with humanized antibodies are suitable for immunodeficient xenograft tumor models. In contrast, Mouse CD3/CD28 ActiveBeads™ with anti-mouse antibodies are ideal for immunocompetent syngeneic tumor models to simulate the tumor microenvironment.

Advantages

- High Efficiency: Consistently achieving high rates of T-cell expansion.
- Contamination-Free: Using magnetic beads to support a clean process.
- Preserved Functionality: Maintaining activated T cells in vivo-like function.
- Long-term Utility: Activating and expanding T cells with Human or Mouse CD3/CD28 ActiveBeads™ for three days to several weeks.
- No Feeder Cell: Easily expanding T cells without feeder cells.

Human CD3/CD28 ActiveBeads™

Catalog # U0576

Cell Type: T Cells


Capacity: ≤ 1x108 / enriched T cells or ≤ 2x108 PBMCs

Reactivity: Human


Regulatory Status: For research use only (RUO)

Stimulation

T cell activation status (D1)



T cell activation status (D3)



Mouse CD3/CD28 ActiveBeads™

Catalog # U0600


Cell Type: T Cells


Capacity: ≤ 2.5x108 / enriched T cells or ≤ 6.25x108 splenocytes

Regulatory Status: For research use only (RUO)

Stimulation

T cell activation status (D1)





Reference

- 1. Sudarsanam et al. (2022). Frontiers in Bioengineering and Biotechnology. doi: 10.3389/fbioe.2022.886637
- 2. Poltorak et al. (2020). Scientific Reports. doi: 10.1038/s41598-020-74595-8